Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia.

Low concentrations of imatinib (IM) in bone marrow cells have been linked with poor prognosis in patients with chronic myeloid leukemia (CML), which may be caused by the emergence of ATP-binding cassette transporter B1 (ABCB1) mutations. The aim of present study was to investigate how clinical outcomes vary among patients with different single nucleotide polymorphisms (SNPs) of ABCB1. A total of 48 adult patients with CML and higher than median ABCB1 mRNA levels were selected for testing of ABCB1 SNPs.

[Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].

Objective: To detect the expression of hOCT1 and ABCB1 in marrow cells and examine the efficacy of imatinib mesylate (IM) in patients with chronic myelocytic leukemia (CML).

Methods: hOCT1 and ABCB1 gene in 90 samples with chronic phase CML diagnosed at our hospital from January 2008 and June 2011 were detected by taqman probe real-time reverse transcription-PCR (RT-PCR). The samples were divided into 3 groups: drug-resistant group (n = 17), partial cytological remission (PCyR) group (n = 11) and complete cytogenetic remission (CCR) group (n = 62) according to IM efficacy and 3 - 6, 7 - 12, 13 - 24, 25 - 48, > 48 months five groups (n = 21, 8, 15, 29, 17) according to IM treatment course.

Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.

Background: Trough imatinib plasma concentration, intracellular drug levels and expression of drug transporters can be indicative of clinical responses in chronic myelocytic leukemia (CML) patients receiving imatinib. We aimed to determine plasma imatinib concentration, intracellular imatinib concentration, human organic cation transporter 1 (hOCT1) and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in bone marrow cells of CML patients in order to evaluate the potential usefulness of these measures as markers of imatinib efficacy and understand their clinical relationships.

Methods: Eighty-four CML patients receiving imatinib treatment were included in this study.

[Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].

Objective: To explore the relationship between serum α1-acid glycoprotein (AGP), disease progression, imatinib plasma trough concentration and efficacy in the patients with chronic myeloid leukemia (CML).

Methods: A total of 112 CML patients were recruited from August 2008 to February 2010 in our hospital. There were 72 males and 40 females with a median age of 39 years old (range: 6 - 76 years old).

[A forensic pathological study of eighty-two cases of adrenal hemorrhage].

Objective: To analyze the relationship between adrenal hemorrhage and the cause of death, age and gender.

Methods: Eighty-two cases of adrenal hemorrhage were statistically analyzed.

Results: Adrenal hemorrhage occurred mostly in cases of sudden death, infection, trauma and asphyxia.

[Early diagnosis of the tumors in orbital apex and optic nerve].

Objective: To obtain clues for early diagnosis of the tumors in orbital apex and optic nerve.

Methods: Twenty-two cases (22 eyes) of orbital tumors without proptosis were collected, and their clinical manifestations, especially main or first symptoms, the course of their diagnosis and treatment as well as the data of ultrasonography-B, CT and MRI were analyzed.

Results: Among 22 cases of the orbital tumors, there were 6 cases of cavernous hemangioma, 6 cases of the tumors from paransal sinuses or nasopharyngeal cavity, 4 cases of neurilemmoma and optic nerve sheath meningioma, neurofibroma, and 1 case of optic nerve glioma.